Hepatotoxicity related to Anakinra has been reported in pediatric rheumatology patients. LFT elevations have been reported with IL-1 inhibition, even after excluding LFTs from the inflamm Dx, other drugs, MAS, etc. Here are 3 case reports. https://t.co/P4Vv2L3u24 https://t.co/ZYBPcgXNi8

JAKi Safety and Efficacy in bDMARD-IR Patients with RA View 5-year long-term extension outcomes from the SELECT-BEYOND study in bDMARD-IR patients with RA, including TNFi-IR subgroup outcomes. This poster is sponsored by AbbVie US Medical Affairs.https://t.co/Qr3KJXZJOe https://t.co/Ri1eS0q9Rb

Difficult #PMR Management Featuring Dr. Sebastian Sattui (Pittsburgh, PA) PMR with Difficulty Weaning plus Synovitis. QD Clinics are video vignettes with lessons from the clinic. https://t.co/dLYxwrmbJg @sattuiSEMD https://t.co/FDuHWJT7Ra

PMR & Popeye's Spinach Dr. Jack Cush reviews the big #PMR reports from this week along with other journal reports from RheumNow. https://t.co/7oCQmuSATE https://t.co/5qWfZZzNBn

Dr. Iain McInnes, Glasgow and Dr. Gerd Burmester, Berlin, discuss their perspectives on the future management of people with rheumatoid arthritis #RA https://t.co/BhAKRXuzMY https://t.co/MqVHMieqiz https://t.co/zCvO2FbrZA

FDA has approved IV secukinumab (Cosentyx), an IL-17 inhibitor for use in adults with psoriatic arthritis (PsA), ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA). https://t.co/48QLLoMvUk https://t.co/mf4IBVLZD9

Tuesday 10/10--this webinar focuses on steroid use in #PMR. Join panelists Dr. Max Yates and Dr. Richard Conway. Moderated by Dr. David Liew. https://t.co/4PefLrRoBx @drmaxyates1 @richardpaconway @drdavidliew https://t.co/089UBUsJLj

Sustained Efficacy of Bimekizumab in PsA BE OPTIMAL trial tested the benefits of a dual IL-17 A/F inhibitor, BKZ, in patients with active PsA and showed superior efficacy over placebo, that was sustained beyond the primary endpoint, from week 16 to 52. https://t.co/JQ53JV0dvv https://t.co/RQoIXsVnOr

SAPHYR Trial: Sarilumab Wins in Relapsing Polymyalgia Rheumatica NEJM reported today that #PMR patients who fail to respond to standard doses of prednisone therapy, were significantly better when given the IL-6 inhibitor sarilumab (than placebo). https://t.co/dC9Z7UgkcO https://t.co/44QEittlEX

2005 study of 364 PMR pts (age 73.4 yrs) - 284 Rx w/ steroids, predictors of relapse =higher initial CS dose & faster CS tapering. Relapse 4-fold higher when the CS tapering rate was fast (HR 4.27). Minimize initial CS dose and taper CS slowly!! https://t.co/hUpBO7fEgh https://t.co/fv9txM0BeH

Comparison of 354 527 COVID-19 infected vs 6.1 mill controls shows COVID incr risk of alopecia areata (aHR 1.12), alopecia totalis (aHR 1.74), ANCA vasculitis (aHR 2.76), Crohns (aHR), & sarcoidosis (aHR). https://t.co/enwb2taza4 https://t.co/ljY7uMPIrm